EOLS
Evolus, Inc. Health Care Pharmaceutical Preparations Russell 3000
$7.35Close
$477.8MMarket cap
$3.94 – $9.3052-week range
Nov 4, 2026Next report · after the close
Highlights
Strengths
- Leading the market RS 84 · stronger than 84% of stocks over 12 months
Cautions
- Trend not confirmed 7 of 8 conditions · under the 50-day
- Results soon Nov 4, 2026, in 3 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
21%
1wk
up 4.9%
price change
1mo
down 8.1%
price change
12-month return
up 9%
market up 11% ·
its own down 4%
F-score
3 / 9
Weak
Altman Z
-1.75
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
—
price / book
Earnings yield
down 5.7%
EBIT / enterprise value
Cheaper than
10%
of the market · expensive
Revenue growth
up 12%
year on year
EPS growth
—
latest quarter
Sales growth
up 21%
latest quarter · +14 pts
ROE
—
return on equity
Free cash margin
down 15%
-$45.7M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Piotroski tests
- not yet profitable on its assets
- operating cash flow is negative
- short-term liquidity weakened
- issued more shares
- gross margin narrowed
- assets working less efficiently
- profitability improving
- profits backed by cash
- reduced long-term debt
Trade setup
ATR%
4.9%
$0.36 a day · 2×ATR $6.64
RS
84 / 99
vs the universe
Trend
7 / 8
under the 50-day
Relative volume
1.0×
vs 50-day average
Up/down volume
1.00
50 sessions
Implied move
—
no option chain · report Nov 4, 2026
Trend template · 7 of 8
- Price above the 50-day average: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Liabilities exceed assets Shareholders' equity is negative at -$23.1M as of Dec 31, 2025. What is left for shareholders after creditors is, on the balance sheet, less than nothing.
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Shareholders diluted The share count rose 2.4% over the year, from 63m to 65m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
- Gross margin narrowing Gross margin fell from 68.5% to 66.3%. The company is keeping less of each dollar of sales than it did a year ago.
Last reported
Aug 5, 2026
Results reaction
Aug 5, 2026+21% vs market2 sessions after results
Financials
- Gross 66%
- Net -17%
- Free cash -15%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $56.5M | $99.7M | $148.6M | $202.1M | $266.3M | $297.2M |
| Gross margin | 68% | 56% | 60% | 68% | 68% | 66% |
| Operating income | -$153.1M | -$44.4M | -$65.3M | -$49.2M | -$34.4M | -$32.7M |
| Net income | -$163.0M | -$46.8M | -$74.4M | -$61.7M | -$50.4M | -$51.6M |
| Net margin | -288% | -47% | -50% | -31% | -19% | -17% |
| Earnings per share | -$4.83 | -$0.94 | -$1.33 | -$1.08 | -$0.81 | -$0.80 |
| Free cash flow | -$58.7M | -$33.8M | -$86.5M | -$34.5M | -$19.5M | -$45.7M |
| Free cash margin | -104% | -34% | -58% | -17% | -7% | -15% |
| Cash | $102.6M | $146.3M | $53.9M | $62.8M | $87.0M | $53.8M |
| Long-term debt | — | $71.2M | $71.9M | $120.4M | $121.5M | $146.1M |
| Shareholders' equity | -$73.0M | $81.9M | $18.5M | -$20.7M | $5.5M | -$23.1M |
| Shares outstanding | 33.75m | 55.58m | 56.26m | 57.82m | 63.50m | 65.01m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 5, 2026 | Quarterly ↗ | Jun 30, 2026 | 36d |
| May 4, 2026 | Quarterly ↗ | Mar 31, 2026 | 34d |
| Mar 3, 2026 | Annual ↗ | Dec 31, 2025 | 62d |
| Nov 5, 2025 | Quarterly ↗ | Sep 30, 2025 | 36d |
| Aug 5, 2025 | Quarterly ↗ | Jun 30, 2025 | 36d |
| May 7, 2025 | Quarterly ↗ | Mar 31, 2025 | 37d |
| Mar 4, 2025 | Annual ↗ | Dec 31, 2024 | 63d |
| Nov 6, 2024 | Quarterly ↗ | Sep 30, 2024 | 37d |
| Jul 31, 2024 | Quarterly ↗ | Jun 30, 2024 | 31d |
| May 7, 2024 | Quarterly ↗ | Mar 31, 2024 | 37d |
| Mar 7, 2024 | Annual ↗ | Dec 31, 2023 | 67d |
| Nov 7, 2023 | Quarterly ↗ | Sep 30, 2023 | 38d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 5, 2026 | Results ↗ |
| Aug 4, 2026 | Material agreement · Regulation FD ↗ |
| Jul 8, 2026 | Material agreement · Regulation FD ↗ |
| Jun 12, 2026 | Shareholder vote ↗ |
| May 4, 2026 | Results · Regulation FD ↗ |
| Mar 13, 2026 | Director or officer change ↗ |
| Mar 3, 2026 | Material agreement · Results · New obligation ↗ |
| Jan 9, 2026 | Results ↗ |
| Nov 5, 2025 | Results ↗ |
| Sep 8, 2025 | Director or officer change · Regulation FD ↗ |
| Aug 5, 2025 | Results · Director or officer change ↗ |
| Jun 6, 2025 | Director or officer change · Shareholder vote ↗ |